See also this year's filing and all EDGAR filings for this company.
PDF Report 0001606645_2020_Foamix_Pharmaceuticals_Ltd.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.055236077481840194, 'aggregate_val': 81159000, 'exp_sum': 85904000, 'exp_to_value': {'AssetsCurrent': 76414000, 'AssetsNoncurrent': 4745000, 'PropertyPlantAndEquipmentNet': 2885000, 'Goodwill': 0, 'remainder_Assets': 1860000}} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('EntityCommonStockSharesOutstanding')"} |
Graph
Absolute values for 0001606645, Foamix Pharmaceuticals Ltd.
| xvar | xval | |
|---|---|---|
| 0 | LiabilitiesNoncurrent | 34,258,000 |
| 1 | LiabilitiesCurrent | 29,326,000 |
| 2 | remainder_Liabilities | 0 |
| 3 | AssetsCurrent | 76,414,000 |
| 4 | AssetsNoncurrent | 4,745,000 |
| 5 | PropertyPlantAndEquipmentNet | 2,885,000 |
| 6 | Goodwill | 0 |
| 7 | remainder_Assets | -2,885,000 |
| 8 | GeneralAndAdministrativeExpense | 45,114,000 |
| 9 | ResearchAndDevelopmentExpense | 51,202,000 |
| 10 | remainder_Expenses | 977,000 |
| 11 | remainder_Revenues | 443,000 |
| 12 | remainder_NetIncome | 1,672,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Liabilities | 63,584,000 |
| 1 | Assets | 81,159,000 |
| 2 | Expenses | 97,293,000 |
| 3 | Revenues | 443,000 |
| 4 | StockholdersEquity | 17,575,000 |
| 5 | NetIncome | -95,178,000 |
| 6 | ComprehensiveNetIncome | -95,178,000 |
| 7 | BaseVar | 122,075,500 |
| 8 | EconomicCapitalRatio | -1.11 |
Edgar->Model Mapping
Feature Distribution
Change over Time
